Share on Pinterest Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Shelby Knowles/Bloomberg via Getty Images Zepbound led to more long ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...

Shares of Eli Lilly (LLY) climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Lilly's Zepbound shows 47% more weight loss than Wegovy in trial First study comparing the drugs under same trial parameters Novo to wait for full trial data, flags Wegovy's heart benefits The U.S ...

Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight compared to 16% of study participants who took Wegovy. Experts note that weight loss drugs can only be ...

As with any prescription medication, there are side effects of Wegovy to keep in mind. The most common side effects are gastrointestinal ones, like: Some foods may aggravate these side effects ...

Eli Lilly’s shares rose on Wednesday morning after the pharma giant released a study that found its weight loss drug Zepbound helped patients shed more weight than Novo Nordisk’s Wegovy in the first ...